Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
2.
Hepatology ; 47(1): 35-42, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17975791

ABSTRACT

UNLABELLED: A recent nonrandomized pilot trial showed that hepatitis C virus (HCV) patients with genotype 2/3 and rapid virological response (RVR) had a 90% sustained virological response (SVR) rate after 14 weeks of treatment. We aimed to assess this concept in a randomized controlled trial. In the trial, 428 treatment-naïve HCV RNA-positive patients with genotype 2 or 3 were enrolled. Patients with RVR were randomized to 14 (group A) or 24 (group B) weeks of treatment. Patients were treated with pegylated interferon alpha-2b (1.5 microg/kg) subcutaneously weekly and ribavirin (800-1400 mg) orally daily. The noninferiority margin was set to be 10% between the two groups with a one-sided 2.5% significance level. RVR was obtained in 302 of 428 (71%), and 298 of these were randomized to group A (n = 148) or group B (n = 150). In the intention-to-treat analysis, SVR rates were 120 of 148 (81.1%) in group A and 136 of 150 (90.7%) in group B (difference, 9.6%; 95% confidence interval, 1.7-17.7). Among patients with an HCV RNA test 24 weeks after the end of treatment, 120 of 139 (86.3%) patients in group A achieved SVR compared with 136 of 146 (93.2%) in group B (difference, 6.9%; 95% confidence interval, -0.1 to +13.9). CONCLUSION: We cannot formally claim that 14 weeks of treatment is noninferior to 24 weeks of treatment. However, the SVR rate after 14 weeks of treatment is high, and although longer treatment may give slightly better SVR, we believe economical savings and fewer side effects make it rational to treat patients with genotype 2 or 3 and RVR for only 14 weeks.


Subject(s)
Antiviral Agents/administration & dosage , Hepacivirus/drug effects , Hepatitis C/drug therapy , Interferon-alpha/administration & dosage , Ribavirin/administration & dosage , Adolescent , Adult , Aged , Antiviral Agents/adverse effects , Antiviral Agents/economics , Drug Administration Schedule , Drug Therapy, Combination , Female , Genotype , Hepacivirus/genetics , Humans , Interferon alpha-2 , Interferon-alpha/adverse effects , Interferon-alpha/economics , Male , Middle Aged , Polyethylene Glycols , Recombinant Proteins , Ribavirin/adverse effects , Ribavirin/economics , Viral Load/statistics & numerical data
3.
Hepatology ; 40(6): 1260-5, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15558712

ABSTRACT

The aim of this study was to determine the efficacy of 14 weeks of treatment in patients infected with hepatitis C virus (HCV) genotype 2 or 3 who achieve early virological response (EVR). In a noncontrolled multicenter trial, 122 treatment-naive patients received 1.5 mug/kg pegylated interferon alfa-2b subcutaneously once weekly and 800 to 1,400 mg/d ribavirin based on body weight. Treatment was stopped at week 14 in patients with EVR, defined as undetectable HCV RNA at weeks 4 and 8. Patients without EVR were assigned to 24 weeks of treatment. The primary end point was sustained virological response (SVR), defined as undetectable HCV RNA 24 weeks after end of treatment. Among the 122 patients, 95 (78%) had EVR and received 14 weeks of treatment. The remaining 27 (22%) were treated for 24 weeks. SVR was obtained in 85 (90%) of 95 patients in the 14-week treatment group and 15 of (56%) 27 in the 24-week treatment group. Altogether, SVR was obtained in 100 of 122 patients (82%; 95% CI, 75%-89%). SVR after 14 weeks of treatment was achieved more frequently among genotype 3a patients with low viral load compared with high viral load (98% vs. 79%; P = .019). Logistic regression analysis showed that absence of bridging fibrosis/cirrhosis was the only independent predictor of SVR. In conclusion, patients with genotype 2 or 3 and EVR obtained a high SVR after 14 weeks of treatment. The results need to be confirmed in a randomized, controlled study before this treatment approach can be recommended, particularly for patients with genotype 3 and high viral load or severe fibrosis.


Subject(s)
Antiviral Agents/administration & dosage , Hepacivirus/genetics , Hepatitis C, Chronic/drug therapy , Interferon-alpha/administration & dosage , Ribavirin/administration & dosage , Adult , Antiviral Agents/adverse effects , Biopsy , Drug Therapy, Combination , Female , Genotype , Hepatitis C, Chronic/pathology , Humans , Interferon alpha-2 , Interferon-alpha/adverse effects , Male , Middle Aged , Multivariate Analysis , Pilot Projects , Polyethylene Glycols , Predictive Value of Tests , RNA, Viral/analysis , Recombinant Proteins , Recurrence , Ribavirin/adverse effects , Treatment Outcome
4.
Tidsskr Nor Laegeforen ; 124(17): 2259-60, 2004 Sep 09.
Article in Norwegian | MEDLINE | ID: mdl-15356694

ABSTRACT

BACKGROUND: Medication errors may have serious consequences for patients and erroneous drug charts represent one of several causes of error. As part of a quality assurance survey, we studied whether user documentation on the charts was in accordance with the guidelines for chart keeping. MATERIAL AND METHODS: On the same day, the drug charts of all hospitalized patients (n = 401) were copied and a representative sample of 207 charts was reviewed. RESULTS: 15 charts had no prescriptions; 14 of the remaining 192 charts (7 %) were correctly filled in. 152 charts (79 %) had deviations that we considered might pose only minor potential health risk; 26 (14 %) had deviations implying potential risk. No charts had deviations considered to pose major risk. INTERPRETATION: Several deviations from the guidelines were found and better training is needed; we recommend standardisation of drug charts and guidelines.


Subject(s)
Drug Prescriptions/standards , Medical Records/standards , Medication Errors , Medication Systems, Hospital/standards , Documentation/standards , Humans , Medication Errors/prevention & control , Norway , Practice Guidelines as Topic/standards , Quality Assurance, Health Care , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...